Benjamin Lee

Dr. Benjamin Lee

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2018 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
BLBohao Liu
Bohao Liu
BLBenjamin Lee
Benjamin Lee
KNKoki Nakanishi
Koki Nakanishi
Aranzazu VillasanteAranzazu Villasante
Aranzazu Villasante
RWRebecca Williamson
Rebecca Williamson
Gordana Vunjak-NovakovicGordana Vunjak-Novakovic
Gordana Vunjak-Novakovic

19 January 2016 in Nature Communications
Verified
Journal Article
Open access
GEGeorge Eng
George Eng
BLBenjamin Lee
Benjamin Lee
LPLev Protas
Lev Protas
MGMark Gagliardi
Mark Gagliardi
KBKristy Brown
Kristy Brown
Gordana Vunjak-NovakovicGordana Vunjak-Novakovic
Gordana Vunjak-Novakovic
The therapeutic success of human stem cell-derived cardiomyocytes critically depends on their ability to respond to and integrate with the surrounding electromechanical environment. Currently, the immaturity of human cardiomyocytes derived from stem cells limits their utility for regenerative medicine and biological research. We hypothesize that biomimetic electrical signals regulate the intrinsic beating properties of cardiomyocytes. Here we show that electrical conditioning of human stem cell-derived cardiomyocytes in three-dimensional culture promotes cardiomyocyte maturation, alters their automaticity and enhances connexin expression. Cardiomyocytes adapt their autonomous beating rate to the frequency at which they were stimulated, an effect mediated by the emergence of a rapidly depolarizing cell population, and the expression of hERG. This rate-adaptive behaviour is long lasting and transferable to the surrounding cardiomyocytes. Thus, electrical conditioning may be used to promote cardiomyocyte maturation and establish their automaticity, with implications for cell-based reduction of arrhythmia during heart regeneration.

1 January 2016 in Theranostics
Verified
Journal Article
Open access
Aranzazu VillasanteAranzazu Villasante
Aranzazu Villasante
AMAlessandro Marturano-Kruik
Alessandro Marturano-Kruik
SASrikanth R. Ambati
Srikanth R. Ambati
ZLZen Liu
Zen Liu
AGAmandine Godier-Furnemont
Amandine Godier-Furnemont
Gordana Vunjak-NovakovicGordana Vunjak-Novakovic
Gordana Vunjak-Novakovic
There is a growing interest in the pivotal role of exosomes in cancer and in their use as biomarkers. However, despite the importance of the microenvironment for cancer initiation and progression, monolayer cultures of tumor cells still represent the main in vitro source of exosomes. As a result, their environmental regulation remains largely unknown. Here, we report a three-dimensional tumor model for studying exosomes, using Ewing's sarcoma type 1 as a clinically relevant example. The bioengineered model was designed based on the hypothesis that the 3-dimensionality, composition and stiffness of the tumor matrix are the critical determinants of the size and cargo of exosomes released by the cancer cells. We analyzed the effects of the tumor microenvironment on exosomes, and the effects of exosomes on the non-cancer cells from the bone niche. Exosomes from the tissue-engineered tumor had similar size distribution as those in the patients' plasma, and were markedly smaller than those in monolayer cultures. Bioengineered tumors and the patients' plasma contained high levels of the Polycomb histone methyltransferase EZH2 mRNA relatively to their monolayer counterparts. Notably, EZH2 mRNA, a potential tumor biomarker detectable in blood plasma, could be transferred to the surrounding mesenchymal stem cells. This study provides the first evidence that an in vitro culture environment can recapitulate some properties of tumor exosomes.

5 November 2008 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
HPHesam Parsa
Hesam Parsa
CCCurtis D. Chin
Curtis D. Chin
PMPuttisarn Mongkolwisetwara
Puttisarn Mongkolwisetwara
BLBenjamin Lee
Benjamin Lee
JWJennifer J. Wang
Jennifer J. Wang
SSSamuel K. Sia
Samuel K. Sia
Despite the prevalence of microfluidic-based heterogeneous immunoassays (where analytes in solution are captured on a solid surface functionalized with a capture molecule), there is incomplete understanding of how assay parameters influence the amount of captured analytes. This study presents computational results and corresponding experimental binding assays in which the capture of analytes is studied under variations in both mass transfer and surface binding, constrained by real-world assay conditions of finite sample volume, assay time, and capture area. Our results identify: 1) a “reagent-limited” regime which exists only under the constraints of finite sample volume and assay time; 2) a critical flow rate (e.g. 0.5 µL min−1 under our assay conditions) to gain the maximum signal with the fastest assay time; 3) an increase in signal by using a short concentrated plug (e.g. 5 µL, 100 nM) rather than a long dilute plug (e.g. 50 µL, 10 nM) of sample; 4) the possibility of spending a considerable fraction of the assay time out of the reaction-limited regime. Overall, an improved understanding of fundamental physical processes may be particularly beneficial for the design of point-of-care assays, where volumes of reagents and available samples are limited, and the desired time-to-result short.

4 March 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GEGeorge Eng
George Eng
BLBenjamin Lee
Benjamin Lee
HPHesam Parsa
Hesam Parsa
CCCurtis D. Chin
Curtis D. Chin
JSJesse Schneider
Jesse Schneider
Gordana Vunjak-NovakovicGordana Vunjak-Novakovic
Gordana Vunjak-Novakovic
Cellular communities in living tissues act in concert to establish intricate microenvironments, with complexity difficult to recapitulate in vitro. We report a method for docking numerous cellularized hydrogel shapes (100–1,000 µm in size) into hydrogel templates to construct 3D cellular microenvironments. Each shape can be uniquely designed to contain customizable concentrations of cells and molecular species, and can be placed into any spatial configuration, providing extensive compositional and geometric tunability of shape-coded patterns using a highly biocompatible hydrogel material. Using precisely arranged hydrogel shapes, we investigated migratory patterns of human mesenchymal stem cells and endothelial cells. We then developed a finite element gradient model predicting chemotactic directions of cell migration in micropatterned cocultures that were validated by tracking ∼2,500 individual cell trajectories. This simple yet robust hydrogel platform provides a comprehensive approach to the assembly of 3D cell environments.

17 July 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
DEDeborah M. Eaton
Deborah M. Eaton
BLBenjamin Lee
Benjamin Lee
MCMatthew A. Caporizzo
Matthew A. Caporizzo
AIAmit Iyengar
Amit Iyengar
CCChristina Y. Chen
Christina Y. Chen
KMKenneth B. Margulies
Kenneth B. Margulies
Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome associated with increased myocardial stiffness and cardiac filling abnormalities. Prior studies implicated increased α-tubulin detyrosination, which is catalyzed by the vasohibin enzymes, as a contributor to increased stabilization of the cardiomyocyte microtubule network (MTN) and stiffness in failing human hearts. We explored whether increased MTN detyrosination contributed to impaired diastolic function in the ZSF1 obese rat model of HFpEF and designed a small-molecule vasohibin inhibitor to ablate MTN detyrosination in vivo. Compared with ZSF1 lean and Wistar Kyoto rats, obese rats exhibited increased tubulin detyrosination concomitant with diastolic dysfunction, left atrial enlargement, and cardiac hypertrophy with a preserved left ventricle ejection fraction, consistent with an HFpEF phenotype. Ex vivo myocardial phenotyping assessed cardiomyocyte mechanics and contractility. Vasohibin inhibitor treatment of isolated cardiomyocytes from obese rats resulted in reduced stiffness and faster relaxation. Acute in vivo treatment with vasohibin inhibitor improved diastolic relaxation in ZSF1 obese rats compared with ZSF1 lean and Wistar Kyoto rats. Vasohibin inhibition also improved relaxation in isolated human cardiomyocytes from both failing and nonfailing hearts. Our data suggest the therapeutic potential for vasohibin inhibition to reduce myocardial stiffness and improve relaxation in HFpEF.